araag2/HINT huggingface dataset:
Clinical trial NCT01316939 (phase 3, status: terminated)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: gsk1605786a, placebo, gsk1605786a
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    this study was terminated due to the lack of efficacy of gsk1605786a in crohn's disease based
    on the results of study ccx114151.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects achieving clinical response (CDAI decrease of at least 100 points) and/or
             remission (CDAI less than 150) upon completion of treatment in Study CCX114151 or
             another GSK sponsored induction study

          -  Written informed consent prior to any CCX114157 specific study procedures

          -  Females of child-bearing potential must be sexually inactive or commit to use of
             consistent and correct use of contraceptive methods with a failure rate of less than 1
             percent

          -  Stable doses of Crohn's disease medications

          -  Subjects on corticosteroids at entry must be willing to undergo corticosteroid dose
             taper during the study

        Exclusion Criteria:

          -  If female, is pregnant, has a positive pregnancy test or is breast-feeding

          -  Subjects with known or suspected coeliac disease or a positive screening test
             (anti-tissue transglutaminase antibodies) should have been excluded from enrolment
             into the induction studies. Subjects in whom a diagnosis of coeliac disease is
             subsequently suspected should have this excluded with testing for anti-tissue
             transglutaminase antibodies prior to enrolment into the maintenance study.

          -  Known or suspected fixed symptomatic small bowel stricture

          -  Enterocutaneous, abdominal or pelvic fistulae likely to require surgery during the
             study period

          -  Current sepsis or infections requiring intravenous antibiotic therapy for greater than
             2 weeks

          -  Evidence of hepatic dysfunction, viral hepatitis, or liver function abnormalities
Clinical trial NCT00371683 (phase 3, status: completed)
Conditions: deep vein thrombosis, pulmonary embolism
ICD codes: I82.491, I82.492, I82.493, I82.499, I82.591, I82.592, I82.593, I27.82, Z86.711, I26.01, I26.09, I26.90, I26.99, I26.93
Drugs: enoxaparin + placebo, apixaban + placebo
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Men and non-pregnant, non-breastfeeding women

          -  18 years or older

          -  Scheduled for knee replacement surgery

        Key Exclusion Criteria:

          -  hereditary or acquired bleeding disorders

          -  clotting disorders

          -  bleeding or high risk for bleeding

          -  drugs that affect bleeding or coagulation

          -  need for ongoing parenteral or oral anticoagulation
Clinical trial NCT00284934 (phase 3, status: completed)
Conditions: kidney diseases
ICD codes: I12.9, N18.9, Q61.9, I12.0, D63.1, N18.1, N18.5
Drugs: enteric-coated mycophenolate sodium (ec-mps), tacrolimus, corticosteroids
SMILES: COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Primary or secondary kidney transplant

          -  Treatment with mycophenolic acid (MMF 1 g/d or EC-MPS 720 mg/d) and tacrolimus (trough
             concentration [C0] ≥ 5.5 ng/mL)

          -  Creatinine clearance ≥ 30 mL/min and < 60 mL/min and stable renal function

        Exclusion Criteria:

          -  Multi-organ recipients or previous transplant with any other organ different from
             kidney

          -  Biopsy proven acute rejection or treated acute rejection within the last 3 months.

          -  Prescription of mycophenolate mofetil 1 g/d or mycophenolate sodium 720 mg/d due to
             adverse event occurrence when higher doses were administered

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT01377194 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: levomilnacipran er, levomilnacipran er, placebo
SMILES: CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1, CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women, 18-75 years old

          -  Currently meet the DSM-IV-TR criteria for Major Depressive Disorder

          -  The patient's current depressive episode must be at least 6 weeks in duration

        Exclusion Criteria:

          -  Women who are pregnant, women who will be breastfeeding during the study, and women
             with childbearing potential who are not practicing a reliable method of birth control.

          -  Patients who are considered a suicide risk

          -  Patients with a history of meeting DSM-IV-TR criteria for

          -  a. any manic or hypomanic episode

          -  b. schizophrenia or any other psychotic disorder

          -  c. obsessive-compulsive disorder.
Clinical trial NCT00439647 (phase 3, status: completed)
Conditions: male osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: zoledronic acid 5 mg iv, placebo
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        • Osteoporosis as defined by very low bone mineral density in the hip and spine or low bone
        mineral density in the hip combined with presence of 1-3 mild or moderate fractures of the
        vertebrae

        Exclusion Criteria:

          -  Low Vitamin D

          -  Renal insufficiency

          -  Previous treatment with certain anti-osteoporotic therapies (except after certain
             washout periods): calcitonin, bisphosphonates, parathyroid hormone (PTH), sodium
             fluoride, strontium ranelate,

          -  Previous treatment with testosterone, anabolic steroids or growth hormone

          -  Chronic use of systemic corticosteroids (oral or i.v.) within the last year

          -  History of any cancer or metastases within the last 5 years

          -  History of brittle bone disease, multiple myeloma, or Paget's disease, or any other
             metabolic bone disease, except osteoporosis

          -  Bilateral hip replacements

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01129856 (phase 3, status: completed)
Conditions: dry eye
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: dexamethasone phosphate ophthalmic solution, sodium citrate buffer solution
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Have a reported history of dry eye in each eye

          -  Be at least 12 years of age

          -  Demonstrate a response when exposed to the Controlled Adverse Environment model at
             Visits 1 and 2

        Exclusion Criteria:

          -  Have contraindications to the use of the test articles

          -  Have known allergy or sensitivity to the study medications or their components

          -  Have any ocular infections, active ocular inflammation, or preauricular
             lymphadenopathy

          -  Be current contact lens wearers or wear contacts during the study
Clinical trial NCT01169558 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bevacizumab, fluoropyrimidine-based chemotherapy
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Previously untreated metastatic colon or rectal cancer;

          -  Scheduled to begin fluoropyrimidine-based chemotherapy as a first line treatment.

        Exclusion Criteria:

          -  Prior chemotherapy for metastatic colon or rectal cancer;

          -  Planned radiotherapy for underlying disease;

          -  central nervous system metastases;

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             before study start.
Clinical trial NCT00056329 (phase 3, status: unknown status)
Conditions: down syndrome, alzheimer disease
ICD codes: Q90.9, G30.8, G30.9, G30.0, G30.1
Drugs: vitamin e, multivitamin, placebo
SMILES: CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C, CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Presence of clinically determined Down syndrome (karyotypes optional).

          -  Medically stable.

          -  Medications stable over 3 months.

          -  Appropriately signed and witnessed consent form.

          -  Involvement/cooperation of informant/caregiver.

        Exclusion Criteria:

          -  Medical/neurological condition (other than Alzheimer's disease) associated with
             dementia.

          -  Brief Praxis Test score <20.

          -  Modified Hachinski score >4.

          -  Major depression within 3 months.

          -  History of any disorder of blood coagulation (inherited or acquired).

          -  Current use of anti-coagulants.

          -  Use of experimental medications within 3 months.

          -  Regular use of vitamin E greater than 50 units per day during the previous 6 months.
Clinical trial NCT00619359 (phase 3, status: completed)
Conditions: chemotherapy-induced nausea and vomiting (cinv)
ICD codes: D61.810
Drugs: comparator: fosaprepitant dimeglumine, comparator: aprepitant, dexamethasone, dexamethasone, ondansetron
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is male or female and is at least 18 years of age; scheduled to receive his or
             her first course of cisplatin chemotherapy at a dose of 70 mg/m2 or higher; predicted
             life expectancy of 3 months or greater

          -  Patient is post menopausal or, if premenopausal, must use double-barrier contraception

        Exclusion Criteria:

          -  Patient has symptomatic primary or metastatic CNS malignancy

          -  Patient has received or will receive Radiation therapy to the abdomen or pelvis in the
             week prior to Treatment Day 1 though Day 6

          -  Patient has vomited in the 24 hours prior to treatment Day 1

          -  Patient has an active infection; Patient uses illicit drugs or has current evidence of
             alcohol abuse

          -  Patient is pregnant or breast feeding
Clinical trial NCT01045161 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: aclidinium bromide, placebo
SMILES: OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A diagnosis of stable moderate to severe COPD as defined by the Global Initiative for
             Chronic Obstructive Lung Disease (GOLD) guidelines, 2008; postbronchodilator FEV1/FVC
             < 70%, and postbronchodilator FEV1 ≥ 30% and < 80% predicted

          -  Current or former cigarette smokers

        Exclusion Criteria:

          -  Patients who have been hospitalized for an acute COPD exacerbation within 3 months
             before the first visit

          -  Respiratory tract infection or COPD exacerbation in the 6 weeks before Visit 1

          -  Patient with any clinically significant respiratory conditions other than COPD,
             cardiovascular conditions or mental illness

          -  History or presence of asthma verified from medical records

          -  Chronic use of oxygen therapy greater than or equal to 15 hours per day

          -  Patient with uncontrolled infection due to HIV and/or active hepatitis

          -  Patients with a history of hypersensitivity reaction to inhaled anticholinergics

          -  Patients with clinically significant cardiovascular conditions, including myocardial
             infarction during the previous 6 months, newly diagnosed arrhythmia within the
             previous 3 months, unstable angina, unstable arrhythmia that had required changes in
             pharmacological therapy or other intervention.
Clinical trial NCT00627523 (phase 3, status: completed)
Conditions: infant, small for gestational age
ICD codes: O12.00, O12.01, O12.02, O12.03, O12.04, O12.10, O12.11
Drugs: genotropin (pn-180,307) somatropin, control-no treatment
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

        Caucasian male or female subjects aged between 19-29 months at Screening Visit 1.

        Born SGA (birth length and/or weight <-2 SD for gestational age, using country-specific
        standards).

        Height below -2.5 SD at screening (19-29 months of age). At least one measurement of length
        between 12 and 18 months of age. Normal karyotype in girls to exclude Turners syndrome.

        Exclusion Criteria:

        Severe Intra-Uterine Growth Retardation (IUGR) (birth length below - 4 SD for gestational
        age), if associated with dysmorphic features.

        Severe prematurity (Gestational Age (GA) <32 weeks of gestation). Ongoing catch-up growth
        (defined as growth velocity SDS at inclusion >0) based on at least 4 months measurement
        interval).

        Severe familial short stature defined as: Father's height below 155 cm or mother's height
        below 145 cm.

        Defined neurological defects and/or severe neurodevelopmental delay.
Clinical trial NCT01046110 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec, sitagliptin
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes (diagnosed clinically) for at least 6 months

          -  Ongoing treatment with 1 or 2 of the following OADs (metformin, insulin secretagogue
             (sulphonylurea or glinides) or pioglitazone) in any combination with unchanged dosing
             for at least 3 months prior to Visit 1 with the minimum doses stated: -Metformin:
             alone or in combination (including fixed combination)1500 mg or maximum tolerated dose
             (at least 1000 mg daily) -Insulin secretagogue (sulfonylurea or glinide): minimum half
             of the maximal daily dose according to local labelling -Pioglitazone: minimum half of
             the maximal daily dose according to local labelling or maximum tolerated dose

          -  Body Mass Index (BMI) below or equal to 40.0 kg/m^2

          -  HbA1c 7.5-11.0 % (both inclusive) by central laboratory analysis

        Exclusion Criteria:

          -  Use within the last 3 months prior to Visit 1 of: exenatide, liraglutide,
             rosiglitazone or acarbose

          -  Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke;
             decompensated heart failure New York Heart Association (NYHA) class III or IV;
             myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or
             angioplasty

          -  Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least
             180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)

          -  Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last
             12 months) or hypoglycaemic unawareness as judged by the Investigator or
             hospitalisation for diabetic ketoacidosis during the previous 6 months

          -  Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate

          -  Cancer and medical history hereof (except basal cell skin cancer or squamous cell skin
             cancer)
Clinical trial NCT00246285 (phase 3, status: completed)
Conditions: schizophrenia, psychotic disorders
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F23, F24, F12.159, F12.259, F12.150, F12.151, F12.250
Drugs: risperidone
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of schizophrenia by criteria of Diagnostic and Statistical Manual of Mental
             Diseases, 4th edition (DSM-IV)

          -  expected to benefit from continuous treatment with risperidone, including patients who
             cannot tolerate their current antipsychotic therapy or are still exhibiting symptoms

          -  Positive and Negative Syndrome Scale for Schizophrenia (PANSS) score between 40 and
             120 at start of study (not required for patients continuing from the 2 previous
             studies)

        Exclusion Criteria:

          -  Meet criteria for other psychiatric disorders or mental retardation (documented IQ
             <70)

          -  history of substance dependence (including alcohol, but excluding nicotine and
             caffeine)

          -  hypersensitivity or intolerance to risperidone

          -  extrapyramidal symptoms (EPS) such as tremor that are not adequately controlled with
             medication
Clinical trial NCT00134485 (phase 3, status: completed)
Conditions: hypercholesterolemia, familial, hyperlipidemia
ICD codes: E78.01, Z83.42, E78.2, E78.49, E78.5
Drugs: torcetrapib/atorvastatin, atorvastatin
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Heterozygous Familial Hypercholesterolemia

          -  At least 18 years of age

        Exclusion Criteria:

          -  Women who are pregnant or lactating, or planning to become pregnant.

          -  Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor)
             therapy other than atorvastatin or other concomitant therapy with known lipid altering
             effects on LDL-C and HDL-C including fibrates and nicotinic acid (high doses)

          -  Subjects taking any drugs known to be associated with an increased risk of myositis in
             combination with HMG-CoA reductase inhibitors

          -  Subjects with any other medical condition or laboratory abnormality which could affect
             subject safety, preclude evaluation of response, or render unlikely that the subject
             would complete the study
Clinical trial NCT00363727 (phase 3, status: completed)
Conditions: parkinson's disease, parkinson disease, dyskinesias
ICD codes: G20, G20
Drugs: ropinirole controlled-release (requip cr) for rls
SMILES: CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Must be on 600mg or less of levodopa therapy for two years or less.

          -  Must be on a stable dose of levodopa therapy for at least 4 weeks prior to screening.

        Exclusion Criteria:

          -  Current or past history of Dyskinesia.

          -  State of dementia or have a MMSE score < 26 at screening.
Clinical trial NCT00078039 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone er
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Double-blind phase: DSM-IV diagnosis of schizophrenia at least 1 year prior to
             screening

          -  experiencing an acute episode, with a total PANSS score at screening between 70 and
             120

          -  agree to voluntary hospitalization for a minimum of 14 days

          -  willing and able to fill out self-administered questionnaires

          -  able to be compliant with self-administration of medication, or have consistent
             help/support available.

        Open-label extension phase: completed the 6 weeks of double-blind treatment or completed at
        least 21 days of treatment and discontinued due to lack of efficacy

          -  patient and investigator agree that open-label treatment is in the best interest of
             the patient.

        Exclusion Criteria:

          -  Double-blind phase: DSM-IV axis I diagnosis other than schizophrenia

          -  DSM-IV diagnosis of substance dependence within 6 months prior to screening evaluation
             (nicotine and caffeine dependence are not exclusionary)

          -  history of tardive dyskinesia or neuroleptic malignant syndrome (NMS)

          -  history of any severe preexisting gastrointestinal narrowing (pathologic or
             iatrogenic)

          -  previous history of lack of response (2 adequate trials) to any antipsychotic

          -  significant risk of suicidal or violent behavior. Open-label phase: At significant
             risk for suicidal or violent behavior

          -  received an injection of a depot antipsychotic since entry into the preceding
             double-blind phase.
Clinical trial NCT01433523 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: alk hdm ait placebo, alk hdm ait 6 du, alk hdm ait 12 du
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  A clinical relevant history consistent with house dust mite induced asthma of at least
             1 year prior to trial entry.

          -  Use of an appropriate amount of inhaled corticosteroid for the control of asthma
             symptoms.

          -  Documented reversible airway obstruction.

          -  Suitable level of asthma control.

          -  FEV1 ≥ 70% of predicted value.

          -  Positive Skin Prick Test response to Der pte and/or Der far.

          -  Positive specific IgE against Der pte and/or Der far (≥ IgE Class 2; ≥ 0.70 KU/L).

        Key Exclusion Criteria:

          -  A clinical history of persistent allergic asthma or rhinitis caused by an allergen to
             which the subject is regularly exposed and sensitised (except house dust mites).

          -  A clinical history of intermittent allergic asthma or rhinitis if the seasonal
             allergen is causing symptoms in the period from October to March.

          -  Any clinically relevant chronic disease.